Peter Slover
About Peter Slover
Peter T. Slover is Chief Financial Officer of Contineum Therapeutics (CTNM) and has served in the role since September 2020. He is 50, a CPA (California, inactive), and holds a B.S. in Business Administration from Shippensburg University. Prior roles include CFO at Sophiris Bio (2013–2020), finance leadership at Anadys (2004–2012), and seven years as an auditor at KPMG LLP; he is CTNM’s Principal Financial Officer and Principal Accounting Officer and signs SEC filings (10‑Q/8‑K) in that capacity . Company performance context: CTNM reported EBITDA of $16.27M* in FY 2023, then −$50.64M* in FY 2024, with Cash from Operations $19.35M* in FY 2023 and −$32.85M* in FY 2024; revenues were $50.0M* in FY 2023 (J&J PIPE‑307 upfront) and not applicable in FY 2024 given development-stage status . Values retrieved from S&P Global.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Contineum Therapeutics | Chief Financial Officer (Principal Financial Officer & Principal Accounting Officer) | Since Sep-2020 | Public company finance leadership; signed 10-Q/8-K certifications |
| Sophiris Bio | Chief Financial Officer; Head of Finance/PAO | 2013–2020 | Led public biotech finance and reporting |
| Anadys | VP Finance & Operations; Sr Director Finance & Controller; Manager Financial Reporting | 2004–2012 | Built finance ops, internal controls |
| KPMG LLP | Auditor | Seven years | Public accounting audit experience |
Fixed Compensation
- CTNM’s 2025 proxy discloses named executive pay for CEO, former CMO, and General Counsel; CFO compensation specifics (base salary, target bonus %, actual bonus) are not individually disclosed as Mr. Slover was not a named executive officer for FY 2024 .
Performance Compensation
- CTNM employs a short‑term incentive program tied to corporate and individual goals (product development, advancement of clinical trials) for named executives; CFO‑specific metrics, weighting, and payouts are not disclosed .
Equity Ownership & Alignment
| Award Type | Grant Date | Shares | Strike | Vesting Schedule | Expiration | Ownership Form |
|---|---|---|---|---|---|---|
| Stock Option (2024 Plan) | 2024-05-24 | 100,000 | $15.76 | 25,000 on 2025-04-05, then 36 equal monthly installments | 2034-05-23 | Direct |
| Stock Option (2024 Plan) | 2025-01-31 | 110,000 | $9.79 | 27,500 on 2026-01-01, then 36 equal monthly installments | 2035-01-30 | Direct |
- Insider selling pressure: The cited Form 4s reflect option grants; no sales are indicated in those filings .
- Hedging/pledging: CTNM prohibits hedging, short sales, publicly‑traded options, and pledging without approval under its Insider Trading Policy .
- Beneficial ownership: The proxy’s individual ownership table lists directors and named executive officers; Mr. Slover is not individually listed (he is not a named executive), though “all executive officers and directors as a group (12 persons)” are reported .
Employment Terms
| Provision | Terms |
|---|---|
| Employment Start Date | CFO since September 2020 |
| Contract Form | Participation in Executive Severance Plan; at‑will employment |
| Severance (no CIC) | Lump sum equal to 12 months base salary plus pro‑rated target bonus; up to 12 months benefits continuation (Tier 2) |
| Change‑in‑Control (CIC) | Lump sum equal to 100% of base salary + 100% of target bonus (Tier 2); full vesting of time‑based equity; performance‑based equity vests at target unless otherwise specified; stock options exercisable for full term; up to 12 months benefits continuation |
| Triggers | Involuntary termination within 90 days pre‑CIC to 18 months post‑CIC (Tier 2) |
| Definitions | Detailed “Cause,” “Good Reason,” “Change in Control” definitions in plan |
| Clawback | SEC/Nasdaq‑compliant clawback adopted at IPO (April 2024); covers last three completed fiscal years for erroneous incentive comp |
| Arbitration/Restrictive Covenants | Mutual arbitration agreement; severance contingent on compliance with confidentiality, non‑competition, non‑solicitation, non‑disparagement |
Company Performance Context
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenues ($USD) | $50.0M* | N/A* |
| EBITDA ($USD) | $16.27M* | −$50.64M* |
| Cash from Operations ($USD) | $19.35M* | −$32.85M* |
| Values retrieved from S&P Global. |
Governance and Committee Interface
- Compensation committee composition: Brady (Chair), Schimmelpennink, Ware; Alpine Rewards retained in Sep‑2024 as independent compensation consultant .
- CFO role in governance: Mr. Slover assists the compensation committee with executive, director, and employee compensation deliberations (does not determine his own pay) .
- Board independence and committee charters disclosed; CFO is not a director .
Related Party and Strategic Transactions
- J&J PIPE‑307 license: $50.0M upfront; up to ~$1.0B milestones; tiered royalties in low‑double‑digit to high‑teen percents—strategic funding and risk‑sharing context during CFO tenure .
Investment Implications
- Alignment: Two sizable multi‑year option grants with standard 4‑year vesting and CIC acceleration indicate equity‑based alignment with long‑term value creation; hedging/pledging prohibitions reduce misalignment risk .
- Retention and change‑of‑control: Tier 2 economics (1.0x salary+bonus at CIC termination; full time‑based vesting; options exercisable full term) provide competitive protection without excessive cash multiples, balancing retention with shareholder interests .
- Pay‑for‑performance visibility: CFO‑specific cash compensation metrics are not disclosed, limiting direct pay‑for‑performance assessment; committee oversight and use of an independent consultant are positives .
- Execution risk: Development‑stage losses and negative operating cash flow in FY 2024 underscore financing and clinical execution dependencies; the 2023 J&J license deal provides non‑dilutive capital and validation but royalty/milestone timing remains uncertain .